Sally Allain, M.Sc., M.B.A., is the Head of JLABS @ Washington, DC. Ms. Allain sets the strategic direction and oversees all operational activities for JLABS in the greater Washington metro region, including Maryland and Virginia. In addition to managing the business of JLABS, Ms. Allain is responsible for the process of evaluating, selecting, and accelerating a strong portfolio of innovators for JLABS @ Washington, DC. Drawing on 18 years of experience, Ms. Allain is creating strategic partnerships with corporate, academic, government, and industry organizations, building a strong and dynamic network of innovation for patients and consumers. Ms. Allain joined JLABS after serving as Senior Director, Strategy & Operations, on the Global External Innovation team at Johnson & Johnson, where she drove global external portfolio management and reporting while leading cross-sector engagement, as well as supporting strategic business plan development. Prior, Ms. Allain built a research operations and alliance management team within Immunology to support an early discovery research and development portfolio. She also has experience in roles driving strategic initiatives in translational medicine, the development of partnerships with the Johnson & Johnson Innovation Centers, and driving teams to enhance a positive corporate culture. In addition to her career at Johnson & Johnson, Ms. Allain has had experience in biotech start-ups, as well as working internationally with ITI Life Sciences, a UK governmental economic development agency aimed at developing innovative early-stage biotech and academic collaborative programs. Ms. Allain received her M.B.A. from the University of California, Berkeley, Haas School of Business; an M.Sc. in microbiology/immunology from Virginia Tech; and a B.S. in biology from Virginia Tech.
Ananda Bandyopadhyay, M.B.B.S., M.P.H., considers himself a foot soldier in the battle to eradicate diseases. Dr. Bandyopadhyay grew up in Kolkata, India, and completed his medical graduation from Calcutta National Medical College & Hospital (2005). He received his M.P.H. in global health from the Harvard T.H. Chan School of Public Health (2010). In between (2006–2009), he worked for the polio eradication initiative in India as a Surveillance Medical Officer with the National Polio Surveillance Project of the World Health Organization, and contributed to India’s successful and historic polio elimination effort and measles surveillance initiatives. He worked as an Infectious Disease Epidemiologist at Rhode Island State Department of Health in the United States for 2 years before joining the Bill & Melinda Gates Foundation in 2012. As a Senior Program Officer at the Gates Foundation, he supports global polio vaccine research and product development initiatives across multiple countries and geographies. His research is focused on generating data regarding the best use of polio vaccines to make them affordable and accessible to vulnerable and underserved populations. He is also involved in enhancing and expanding polio environmental surveillance globally with newer tools and diagnostics. His work on clinical development of novel polio vaccines and on polio endgame vaccination schedules has been a factor in global policy formulation and has been published in leading peer-reviewed journals. He is associated with advanced degree programs in public health and vaccinology in several globally renowned teaching venues as a guest faculty member.
Daniel Berman heads up the Global Health team at Nesta Challenges, including managing the Longitude Prize, which is a £10 million project designed to incentivize the development of a rapid diagnostic test to improve the use of antibiotics internationally. Mr. Berman represents Nesta in international One Health forums designed to address the challenge of antimicrobial resistance (AMR). This includes championing new strategies to address the market failure that has led to a lack of diagnostic products to address AMR. He is also exploring new prizes in essential surgery and nonpharmaceutical treatments of chronic pain. Before coming to Nesta, Mr. Berman was a consultant for the World Health Organization in Ethiopia on a local pharmaceutical production project. Previously he was at Médecins Sans Frontières (MSF) for more than 16 years. At MSF he had multiple assignments in the Access to Medicines Campaign, which focuses on stimulating and steering innovation and access to medicines, diagnostics, and vaccines. From 2012 to 2015 Mr. Berman was the General Director of MSF Southern Africa, based in Johannesburg, South Africa. He is currently a Trustee for QUAMED, a French nongovernmental organization that supports humanitarian organizations and national procurement institutions to improve the quality of medicines.
Brian Bird, D.V.M., M.P.H., Ph.D., leads Ebola-related surveillance activities as part of the U.S. Agency for International Development–funded PREDICT program led by the University of California, Davis (UC Davis). Dr. Bird’s work has a particular focus in Guinea, Liberia, and Sierra Leone to identify the animal reservoir origins of ebolaviruses, and to determine if spillover into other animal species occurred during the recent devastating regional outbreak. He is Co-principal Investigator for the Defense Advanced Research Project Agency–funded Preventing Emerging Pandemic Threats project at UC Davis, where he leads in-depth investigations of Lassa fever virus ecology, genomics, and spillover dynamics from rodent reservoirs into humans in West Africa. Previously, Dr. Bird served as a veterinary medical officer for the U.S. Centers for Disease Control and Prevention (CDC) Viral Special Pathogens Branch. He was an early-stage lead of the CDC Emergency Operations Center Laboratory task force during the 2014–2016 West African Ebola epidemic, and then later lead of the CDC field-diagnostic laboratory in Sierra Leone, which successfully and safely tested more than 27,000 specimens from suspected Ebola virus patients
Caroline Buckee M.Res., D.Phil., is an Associate Professor of epidemiology and the Associate Director of the Center for Communicable Disease Dynamics at the Harvard T.H. Chan School of Public Health. She has been working to understand and control infectious diseases among the world’s most vulnerable populations—in particular malaria—since obtaining her D.Phil. from Merton College, Oxford University, in 2006. Following her graduate training, Dr. Buckee won a Sir Henry Wellcome Postdoctoral Fellowship to study malaria in Kenya, and an Omidyar Fellowship at the Santa Fe Institute to harness complex systems approaches in her research. Dr. Buckee’s group is interested in how the ecological and evolutionary aspects of infectious disease transmission lead to patterns of disease in human populations, particularly how human mobility affects the spread of infection. Her group pioneered the use of mobile phone “big data” and pathogen genomics to measure population movement patterns that drive epidemics. She works with malaria control programs and ministries of health in Bangladesh, Colombia, Guyana, India, and Thailand to translate these new data-driven approaches into surveillance and forecasting tools. Most recently, Dr. Buckee led a team to estimate the impact of Hurricane Maria on mortality in Puerto Rico, which was the most widely cited article of 2018. Her work has appeared in high-profile scientific journals such as Science, Nature, and the Proceedings of the National Academy of Sciences of the United States of America, and in the popular press, including CNN, The New Scientist, NPR, BBC, Radio 4, and Voice of America. She was chosen as one of MIT Technology Review’s 35 Innovators Under 35, a CNN Top 10: Thinker, and one of Foreign Policy Magazine’s Global Thinkers.
Lori Burrows, Ph.D., is a microbiologist and international authority on the structure, function, and regulation of type IV pili (T4P), ubiquitous bacterial virulence factors used for adherence, DNA uptake, biofilm formation, and twitching motility. Using the opportunistic pathogen Pseudomonas aeruginosa as a model, her group studies its pilin repertoire (relevant to vaccine design), pilin glycosylation systems involved in bacteriophage defense, structure–function of the pilus assembly system and its integration into the cell envelope, and the complex regulation underlying T4P function. Her lab also studies biofilm formation, particularly stimulation of biofilm development by subinhibitory antibiotic concentrations and exploitation of the stimulation phenotype to find new antimicrobials for multidrug-resistant gram-negative bacteria. Dr. Burrows’s research is funded by the Canadian Institutes of Health Research (CIHR), the Natural Sciences and Engineering Research Council of Canada, the Canadian Glycomics Network, the Ontario Research Fund, and industrial support. She has published more than 100 peer-reviewed papers, reviews, and book chapters. She is the Associate Director (Partnerships and Outreach) of McMaster’s Michael G. DeGroote Institute for Infectious Disease Research and serves on the editorial boards of the Journal of Bacteriology, the Journal of Biochemistry, and the American Chemical Society’s Infectious Diseases. She served as Chair (2010–2017) of the CIHR Microbiology and Infectious Diseases Peer-Review Panel, the Scientific Officer of Cystic Fibrosis Canada’s biomedical grants panel, a member of the Polyani Prize panel, and McMaster University’s CIHR University Delegate since 2012. In 2017 she was elected as a Fellow of the American Academy of Microbiology.
Julio Croda, M.D., Ph.D., is the Chief of the Department of Communicable Diseases at the Secretary of Health Surveillance in Brazil. He is an infectious disease physician-scientist and has served as the Principal Investigator for a series of studies involving active surveillance, molecular epidemiology, and prospective cohort investigations for tuberculosis (TB). He is particularly interested in understanding how prisons contribute globally to TB epidemics, with an ultimate goal of developing more effective interventions to control TB in prisons and communities using translational research and implementation science. Dr. Croda’s training is in epidemiology and clinical medicine, and his work includes epidemiology, fieldwork, and analysis of programmatic data. His research program is currently funded by the National Institutes of Health and by Brazilian research agencies such as the National Council for Scientific and Technological Development and Coordenação de Aperfeiçoamento de Pessoal de Nível Superior.
Rahima Dosani, M.P.H., M.B.A., is a market access advisor at the Center for Innovation and Impact with the U.S. Agency for International De-
velopment’s (USAID’s) Bureau for Global Health. She works on increasing access to global health commodities while improving the functioning of global health markets across disease areas through market shaping efforts, innovative financing structures, private-sector engagement, supply chain improvement, digital health interventions, and human-centered design efforts. Prior to USAID, Ms. Dosani worked at FSG, a social impact consulting firm, where she led global health, international development, and corporate consulting projects. She spent several years living in Malawi and Myanmar working for the Clinton Health Access Initiative, where she served as a technical and strategic advisor to the Ministry of Health to accelerate the introduction of new vaccines, HIV diagnostics, and tuberculosis treatment into both countries. Ms. Dosani began her career in the public sector and health care consulting at PricewaterhouseCoopers Advisory in New York City. She graduated summa cum laude from the University of Pennsylvania, where she studied global health and health care management. Ms. Dosani also holds an M.B.A. from the Harvard Business School and an M.P.H. in global health from the Harvard T.H. Chan School of Public Health, where she was a Zuckerman Fellow through the Harvard University Center for Public Leadership. Ms. Dosani is passionate about social justice, gender equity, and spreading empathy, compassion, and vulnerability to make the world a better place.
Matthew Hepburn, M.D., is the joint product lead at the U.S. Army. He joined the Defense Advanced Research Projects Agency (DARPA) as a Program Manager in 2013. He aims to address the dynamic threats of emerging infectious diseases with potential impact on national security. Prior to joining DARPA, COL Hepburn served as the Director of Medical Preparedness on the White House National Security Staff. Additional previous assignments include Chief Medical Officer at a Level II medical facility in Iraq, Clinical Research Director at the U.S. Army Medical Research Institute for Infectious Diseases, Exchange Officer to the United Kingdom, and Internal Medicine Chief of Residents at Brooke Army Medical Center at Fort Sam Houston, Texas. COL Hepburn completed internal medicine residency and infectious diseases fellowship programs at Brooke Army Medical Center. He holds an M.D. and a B.S. in biomedical engineering from Duke University.
Christine Kreuder Johnson, V.M.D., M.P.V.M., Ph.D., is a professor of epidemiology at the University of California, Davis, and is dedicated to advancing disease investigations at the interface of animal, human, and environmental health through applied research to inform disease prevention and pandemic preparedness. Research activities have sought to investigate the dynamics of high-priority zoonoses and understand the human dimensions of spillover, providing insight for policy changes needed to
mitigate risk and prevent epidemics. She is the Co-principal Investigator of the U.S. Agency for International Development’s (USAID’s) Emerging Pandemic Threats PREDICT program, a 10-year project to detect emerging threats and enhance pandemic preparedness in more than 30 countries, for which she directs surveillance activities in humans and animals. As a multi-institutional consortium, PREDICT has partnered with host country governments to establish an international network of scientists engaged in pathogen discovery, risk characterization, and outbreak response. She has pioneered ecosystem-level studies to investigate the impact of environmental change on population health, and contributes expertise to outbreak investigations at the request of state, federal, and international agencies, including USAID, the U.S. Department of Defense, the California Department of Fish and Wildlife, and the U.S. Fish & Wildlife Service.
Jyoti Joshi, M.D., M.Sc., is the Head of the South Asia Center for Disease Dynamics, Economics & Policy. She has an M.D. with a specialization in community medicine and an M.Sc. in infectious diseases from the London School of Hygiene & Tropical Medicine, University of London. She is also an Adjunct Professor at the Amity Institute of Public Health, Amity University, Noida, India. Dr. Joshi leads several academic research projects in the field of antimicrobial resistance, maternal and child health, immunization, and vaccine safety. As the South Asia lead for the Global Antibiotic Research Partnership (GARP) project, she has supported GARP country working groups to develop antimicrobial resistance (AMR) situation analyses and national action plans. She has advised the World Health Organization in developing guidance for implementing national action plans for AMR. Dr. Joshi co-authored the Scoping Report on the AMR research landscape in India, and is currently implementing two Department of Biotechnology–funded AMR projects in India: “Smart Regulation of Antibiotics in India—Understanding, Innovating, and Improving Compliance,” and “Chicken or Egg: Drivers of Antimicrobial Resistance in Poultry in India (DARPI).” During the course of more than a decade and a half, Dr. Joshi has helped strengthen disease surveillance, immunization, and vaccine pharmacovigilance programs in India and the United Arab Emirates.
Wes Kim, Ph.D., M.B.A., leads efforts to spur the innovation of new antibiotics for Pew’s antibiotic resistance project. His work focuses on research and policies that will help to advance antibiotic discovery and development. Before joining Pew, Dr. Kim was a management consultant in the pharmaceutical and life sciences industry, advising clients on research and development strategy and operations, with a focus on infectious diseases. His clients included multinational companies, philanthropic and donor organizations, U.S. government agencies, and nongovernmental organizations. Before that,
he was a scientist at a biotech start-up, where he led development of a diagnostic kit for breast cancer. Dr. Kim has a bachelor’s degree in biochemistry and religion from Oberlin College and an M.B.A. and a Ph.D. in pharmaceutical sciences from the University of Maryland.
Audrey Lenhart, Ph.D., M.P.H., is a research entomologist at the U.S. Centers for Disease Control and Prevention (CDC) in Atlanta, Georgia. She is based in the Entomology Branch of the Division of Parasitic Diseases and Malaria in the Center for Global Health, where she leads the Insecticide Resistance and Vector Control Team. Dr. Lenhart coordinates the entomology activities in the U.S. Agency for International Development–funded Latin America and Caribbean Regional Malaria Program and managed CDC’s portfolio of international vector-related activities for Zika. Her team provides technical assistance throughout the Americas, Asia, and Africa regarding vector surveillance and control. She leads a research group that focuses on the biology and control of mosquitoes, and her laboratory activities aim to identify the molecular mechanisms that cause insecticide resistance in mosquito vectors of human disease. Dr. Lenhart is a founding member of the Pan American Health Organization’s Technical Advisory Group for Public Health Entomology in the Americas, and is a member of the World Health Organization’s Vector Control Advisory Group. She is an Honorary Research Fellow at the Liverpool School of Tropical Medicine and adjunct faculty in the Department of Environmental Sciences at Emory University.
Fadi Makki, Ph.D., is the Founder of Nudge Lebanon and the Consumer Citizen Lab. He is a pioneer in the application of behavioral economics to public policy in the Middle East and heads the first nudge unit in the Middle East, B4Development (formerly the Qatar Behavioral Insights Unit). He led a large number of randomized controlled trials and behavioral experiments across the Middle East in a variety of policy areas, including health, education, social cohesion, and inclusion. He served between 2016 and 2018 as a member of the World Economic Forum’s Council for the Future of Behavioral Sciences, and is currently a Senior Fellow at Georgetown Qatar and the American University of Beirut’s (AUB’s) Issam Fares Institute of Public Policy. He was Director General of the Lebanese Ministry of Economy & Trade, adviser to the Lebanese Prime Minister. He was previously adviser to the Ministry of Economy and Commerce in Qatar. He worked previously at Booz & Co., and was a visiting fellow/lecturer at the Graduate Institute for International Studies in Geneva, the Lauterpacht Centre at Cambridge University, AUB, and Université Saint Joseph. He earned his Ph.D. from Cambridge University, his master’s from the London School of Economics and Hull University, his bachelor’s degrees from AUB, and his LLB from the Lebanese University. B4Development is the first behavioral
insights and nudge unit in the Middle East, created by the Supreme Committee for Delivery and Legacy, and focusing on policy experimentation, capacity building, and the promotion of the use of evidence-based policy making, such as through behavioral sciences tools and research methods. Nudge Lebanon is a nongovernmental and nonprofit initiative working to apply behavioral insights to the policy challenges that Lebanon faces, using rigorous experimental approaches and tools typically used in the field of behavioral economics, such as randomized controlled trials. Nudge Lebanon is a leader in applying behavioral science to a variety of public policy settings, in particular, improving citizen-centered policies and steering people and organizations toward making the most optimal choices for themselves and their communities.
Collince Osewe is a budding social entrepreneur with both business and software engineering backgrounds. He believes that technology can play a critical role in bridging the inequality gap in child health, especially in enabling last mile access to lifesaving vaccines for the poor, most vulnerable, and highly mobile and impermanent communities. He holds a B.Com. (marketing) degree from the University of Nairobi. He is also well versed in social entrepreneurship, with key competencies in financial modeling for the social sector, marketing to the bottom of the pyramid, measuring social impact, as well as business models for social impact. Having worked at leading social enterprises in Kenya, he has a wealth of experience in project management, including user-centered design approaches, which has been at the core of the ChanjoPlus model. As the Founder and Chief Executive Officer at ChanjoPlus, Mr. Osewe leads strategic planning, partnership development, and fundraising strategy at ChanjoPlus. His motivation to transform the lives of children emanates from a personal experience he had during one of the immunization drives in Nairobi, Kenya, where the majority of children in high mobile urban centers missed their vaccinations and subsequently discontinued their routine immunization schedules due to lack of proper identification, making it a nightmare for health care workers to track which children were falling through the immunization gaps. He created ChanjoPlus to solve this challenge and ensure that every child has access to lifesaving vaccines no matter where they live. Through the ChanjoPlus platform, every registered child is assigned a digital identity that allows health care workers to track which children are missing out on their routine immunization services in real time.
Nitika Pant Pai, M.D., M.P.H., Ph.D., is a tenured Associate Professor at McGill University’s Department of Medicine, Division of Clinical Epidemiology, and Physician Scientist at the Research Institute of the McGill University Health Centre. She is also a member of the New College of Arts
& Sciences of the Royal Society of Canada. Her Global Implementation Research program in Canada, India, and South Africa is focused on point-of-care diagnostics for HIV and associated co-infections (hepatitis C virus [HCV], hepatitis B virus [HBV], human papillomavirus [HPV], and bacterial sexually transmitted infections). Her research informs domestic and global policy on point-of-care diagnostics. She develops and incorporates innovation, implementation science, and artificial intelligence to generate solutions that plug health service delivery gaps. She strives to generate clinical, public health, and social impact. Her innovations are being implemented nationally and internationally. She has been a recipient of many research and innovation awards: Canadian Institutes of Health Research (CIHR) New Investigator award 2010, Fonds de la recherche en santé du Québec (FRSQ) Chercheur Boursier awards 2015, FRSQ senior, 2018, Grand Challenges Canada’s (GCC’s) Stars in Global Health Awards (2011, 2013, 2016), GCC’s Transition to Scale Award (2015), McMaster University’s Chanchalani Award for Research Excellence in HIV 2012, and McGill University’s Maude Abbott Award for Research Excellence 2013, among others. Her research has been supported by grants from the CIHR, the FRSQ Quebec, Grand Challenges Canada, Bill & Melinda Gates Foundation, South African Medical Research Council Strategic Health Innovation Partnerships, and South African Department of Science and Technology. In 2015, she founded a social enterprise, Sympact-X, to take her innovations to scale nationally and internationally. She serves on many technical working groups for national and international agencies: the World Health Organization (WHO), Foundation for Innovative Diagnostics, Geneva; Population Services International Washington; Gates Foundation, Seattle; African Society for Laboratory Medicine (ASLM), Africa; the U.S. Centers for Disease Control and Prevention (CDC)/President’s Emergency Plan for AIDS Relief (PEPFAR), Atlanta; Public Health Agency of Canada, Health Canada, and CIHR REACH. She has advised the U.S. Congress on multiplex testing for sexually transmitted and blood-borne infection (STBBI). In terms of global policies, she has also contributed to ASLM/CDC/PEPFAR’s policies on quality of point-of-care testing (POCT), WHO’s global HIV self-testing guidelines, and WHO’s policy guidance on implementation of HIV self-testing and U.S. policies for POCTs for HIV/STBBI. She has led many systematic reviews to inform the gaps in policies for POCT and on innovations for the Joint United Nations Programme on HIV/AIDS 90-90-90 initiative to end the HIV epidemic. In Canada, she has contributed to the CIHR-REACH–funded national action plan for HIV/STBBI testing. She is a past Co-Chair of the CIHR Reach POCT 2.0 national working group and is working collaboratively to help improve the uptake of POCTs in Canada. As part of these collaborations, she is leading/co-leading three projects: approval of an HIV INSTI self-test; HIVSmart!, a Canada-wide scale up; and AideSmart!,
an app-based screening of multiple co-infections (HCV, syphilis, and HBV) across key Canadian provinces. Funded by Grand Challenges Canada, she and her team developed the world’s first app-based solution for HIV self-testing—the HIVSmart! app—a portable, multilingual, global screening application and platform, which won the ASAP Innovation award ($30,000) from Google, PLOS, and Wellcome Trust at the World Bank in 2013. She has evaluated the HIVSmart! strategy in South Africa/Canada successfully in 3,000 different at risk populations in large-scale implementation studies. The strategy is being adopted by the International Association of Providers of AIDS Care to take to scale in many fast track cities. HIVSmart! has been recently funded to be scaled across Canada. Another app-based strategy to increase the uptake of point-of-care testing by health care workers called AideSmart! (funded by Grand Challenges Canada) has proven results from India. It has been recently funded by CIHR for implementation in Canadian provinces. Funded by the India-Canada Centre for Innovative Multidisciplinary Partnerships to Accelerate Community Transformation and Sustainability, this strategy is being scaled up in at-risk populations in South India. Another of her app-based solutions, HCVSmart!, is a rapid and self-screening strategy for HCV and was featured in the Changemakers section of The Economist in 2017. Her work has been featured in the national and international media: The Economist, MacLeans, The Globe and Mail, Montreal Gazette, Times Now, Times, CTV, CBC, La Presse, and Radio Canada, among others.
Carolina dos S. Ribeiro, M.Sc., Ph.D. candidate, studied veterinary medicine (at the Federal University of Goiás, Brazil) and global health (at the Vrije Universiteit [VU University] Amsterdam, the Netherlands). She works as a policy advisor at the Dutch National Centre for Infectious Disease Control at the Netherlands National Institute for Public Health and the Environment, and is an external Ph.D. student leasing with the Athena Institute from the School of Earth and Life Sciences at the VU University, Amsterdam. Ms. Ribeiro participated as a junior scientist in the COMPARE project, where she researched and produced three reports on addressing the PEARL (political, ethical, administrative, regulatory, and legal) barriers to the sharing of microbial and pathogen genetic data. This involves inter alia in-depth study on ownership barriers to the sharing of microbial genetic resources, performance of workshops with different organizations on the topic of global data sharing, research on the impact of the Nagoya Protocol on the sharing of genetic resources through biobanks and culture collections, research on barriers to the design and implementation of One Health initiatives, and finally research on innovation and product valorization in the field of infectious disease response and control. Currently, Ms. Ribeiro is working on two European and international projects of EVAg (European
Virus Archive goes Global) and VEO (Versatile Emerging infectious disease Observatory). In these projects she is performing research on the implementation of the Nagoya Protocol in a global decentralized collection of microorganisms addressing ethical, legal, and administrative challenges; and on the ethical, legal, and social implications of combining big data with traditional epidemiological and molecular data for enhancing infectious disease management, including through the performance of citizen-aided science.
Senjuti Saha, Ph.D., is a Bangladeshi-Canadian microbiologist working at the intersection of clinical microbiology and global health as a scientist at the Child Health Research Foundation in Bangladesh. After completing her Ph.D. in molecular genetics at the University of Toronto in Canada, she moved back to Bangladesh to pursue a career that brings together basic science and public health. Dr. Saha’s work is grounded in advancing the cause of health and research equity—she believes that everyone across the world should have equal access to the practice and benefits of science. Dr. Saha focuses on pediatric preventable infectious diseases, with the goals of (1) using state-of-the-art technology like on-site metagenomics to identify etiologies that elude standard laboratory testing in low- and middle-income countries, and (2) understanding the indirect impacts of interventions like vaccines on the overall health system. She advocates for equal access to scholarly literature and science education. As a team, their mission is to break free of the vicious cycle of limited resources that leads to lack of data required for evidence-based policy decisions, which leads back to limited resources; instead the team is committed to building virtuous cycles of data generation that are sustainable and cost-effective.
Ranga Sampath, Ph.D., joined the Foundation for Innovative New Diagnostics (FIND) as its Chief Scientific Officer in September 2017, where he leads the organization’s research and development (R&D) and clinical departments, and will contribute to shaping and implementing FIND’s portfolio strategies. Dr. Sampath is a key member of FIND’s Executive Management team, which defines the overall business strategy and direction of the organization, mobilizing resources to enable the implementation of FIND’s mission. Prior to this, Dr. Sampath served as a Volwiler Senior Research Fellow and the Senior Director of R&D for the Ibis Division of Abbott. He led Ibis’s R&D efforts in infectious disease diagnostics, antimicrobial resistance (AMR) diagnostics and surveillance, and was responsible for applications development, validation, data analysis, and reporting for the Ibis polymerase chain reaction/electrospray ionization mass spectrometry–based IRIDICA platform. Dr. Sampath was the cofounder of Ibis Biosciences, Inc., and a co-inventor of the IRIDICA (conformite Europeenne in vitro diagnostic medical) infectious disease diagnostics platform. Dr. Sampath is a
recognized leader in the field, with more than 200 publications and presentations and more than 40 issued patents in infectious disease diagnostics. He was an invited participant at the White House National Forum on Antibiotic Stewardship and was an active member of the AdvamedDx Industry Forum for the global commitment on developing diagnostic tests to fight AMR. He has been an invited speaker at many public forums such as the Institute of Medicine, Infectious Diseases Society of America (IDSA), and Parenteral Drug Association (PDA). He was a key member of a U.S. Food and Drug Administration/PDA task force involved in defining the future of viral screening for cell substrates. Dr. Sampath is currently serving his first of a 3-year term as a member of the Diagnostics Committee for IDSA. His research interests include antimicrobial strategy development, pathogen discovery, fevers of unknown origin, tropical diseases, epidemiological surveillance, and biothreat detection.
Peter Sands, M.P.A., became the Executive Director of The Global Fund to Fight AIDS, Tuberculosis and Malaria in March 2018. Mr. Sands is the former Chief Executive Officer (CEO) of Standard Chartered PLC, one of the world’s leading international banks operating across more than 70 markets, primarily in emerging markets. After a distinguished career in banking, Mr. Sands was a research fellow at the Harvard Global Health Institute and the Mossavar-Rahmani Center for Business and Government at the Harvard Kennedy School, where he immersed himself in a range of global public health projects. In 2016–2017, Mr. Sands chaired the International Working Group on Financing Pandemic Preparedness at the World Bank. In 2015–2016, he was Chair of the U.S. National Academy of Medicine’s Commission on a Global Health Risk Framework for the Future, which published the influential report The Neglected Dimension of Global Security: A Framework to Counter Infectious Disease Threats in January 2016. Mr. Sands is also a member of the U.S. National Academies of Sciences, Engineering, and Medicine’s Forum on Microbial Threats and is serving on a Committee on Ensuring Access to Affordable Drugs. Mr. Sands served as the CEO of Standard Chartered PLC from 2006 to 2015, having joined the bank in 2002 as the Group Finance Director. Under his leadership, Standard Chartered successfully navigated the turbulence of the global financial crisis in 2007–2009, continuing to support clients and counterparties throughout the worst of the financial stresses and without drawing on government support of any kind. Mr. Sands led Standard Chartered’s transformation into one of the world’s leading international banks, reinforcing its focus on emerging markets and driving the development of world-class product, risk management, and technology capabilities, underpinned by a highly collaborative culture. During Mr. Sands’s tenure as the CEO, Standard Chartered focused its corporate responsibility initiatives on health issues, including
avoidable blindness, AIDS, and malaria. Mr. Sands served on the board of the Global Business Coalition on AIDS, Tuberculosis, and Malaria and was the Lead Non-Executive Director on the board of the United Kingdom’s Department of Health. After stepping down from the bank in 2015, Mr. Sands has deployed his skills and experience in international finance in global health. Mr. Sands has chaired and participated in a range of high-profile initiatives and has published articles on global health and epidemics in various peer-reviewed journals. His published works on global health include “The Neglected Dimension of Global Security—A Framework for Countering Infectious-Disease Crises,” in the New England Journal of Medicine, January 2016; “A Stitch in Time Saves Nine: Financing Pandemic Preparedness Through Domestic Resource Mobilization,” Global Health & Diplomacy, April 2016; “Assessing Economic Vulnerability to Infectious Disease Outbreaks,” The Lancet, May 2016; “Beyond the Ebola Battle—Winning the War Against Future Epidemics,” British Medical Journal, January 2017; and “From Panic and Neglect to Investing in Health Security: Financing Pandemic Preparedness at a National Level,” World Bank, May 2017. Mr. Sands has served on numerous boards and commissions, including as a governor of the United Kingdom’s National Institute for Economic and Social Research, as a member of the International Advisory Board of the Monetary Authority of Singapore, as the Board Director of the Institute of International Finance, and as a Director of the World Economic Forum. Born in the United Kingdom, the son of a naval officer and an artist, Mr. Sands was educated in Canada, Malaysia, the United Kingdom, and the United States. He began his career in the United Kingdom’s Foreign Office and then joined McKinsey & Company, where he worked for 13 years in the London office, advising clients in the financial services and telecommunications sectors. Mr. Sands graduated from Brasenose College, Oxford University, with a First Class degree in politics, philosophy, and economics. He also received an M.P.A. from Harvard University, where he was a Harkness Fellow.
Carrie Teicher, M.D., M.P.H., is the Director of Programs at Doctors Without Borders/Médecins Sans Frontières (MSF). The Programs Department supports multiple dossiers including but not limited to work on advocacy, global health diplomacy, research, and innovation. Prior to this role, she worked for 7 years as a medical and surgical epidemiologist with Epicentre (www.epicentre.msf.org), MSF’s internal research and epidemiological institute. Dr. Teicher has worked with MSF in multiple different roles and numerous contexts throughout four continents. Outside of MSF, Dr. Teicher has additionally served as a medical coordinator, primary investigator, or program coordinator in the global health sector working primarily in the emergency medicine and tropical medicine fields. She holds an M.D. from the Sackler School of Medicine, an M.P.H. from the Mailman School
of Public Health at Columbia University, and an undergraduate degree from Barnard College. From 2001 to 2003 she served in the Peace Corps in Mali.
Jonathan Towner, Ph.D., works in the Viral Special Pathogens Branch at the U.S. Centers for Disease Control and Prevention (CDC). His team focuses primarily on ecological aspects of Ebola and Marburg virus biology with emphasis on identifying their reservoir hosts. Dr. Towner’s team also studies the mechanisms used by these viruses to persist in nature long term, and potential drivers of virus spillover to humans. Recent accomplishments include the discovery of the Egyptian fruit bat (Rousettus aegyptiacus), the only known filovirus reservoir, as a natural reservoir for Marburg virus, and the discovery of Bundibugyo ebolavirus, the newest member of the Ebolavirus genus. In addition to his ecological investigations, Dr. Towner responds on occasion to filovirus outbreaks in Africa to operate molecular diagnostic field labs. In this capacity, he has established or operated diagnostic labs at four major filovirus outbreaks since 2000, including the CDC lab in Bo, Sierra Leone, in October 2014. Dr. Towner has been well trained in filovirus biology and ecology by leading authorities in the field, including Drs. Stuart Nichol, Thomas Ksiazek, Robert Swanepoel, and Pierre Rollin. Dr. Towner has more than 22 years of training as a molecular virologist and 17 years of experience conducting virus research under biosafety level-4 containment.
Maurizio Vecchione is the Executive Vice President of Global Good and Research at Intellectual Ventures (IV). In this role, Mr. Vecchione oversees Global Good, IV’s collaboration with Bill Gates to invent and deploy technology specifically focused on improving life in developing countries, as well as the research and operations of the Intellectual Ventures Laboratory (IV Lab) and Institute for Disease Modeling. Under his leadership, Global Good and IV Lab engage in cutting-edge research and invention for the benefit of humanity around global health and global development priorities. He has nearly 30 years of experience in research and the technology sector, most recently serving as the Chief Executive Officer (CEO) of Arrogene and prior to that as the CEO of telemedicine pioneer CompuMed. He has contributed to building 9 start-ups and helped launch more than 50 commercial products, resulting in more than $1 billion in shareholder value. His work spans the software, Internet, wireless, and life sciences sectors, primarily in connection with translational sciences for science derived from government and academic research and development efforts. Mr. Vecchione is involved in several nonprofit initiatives, including his role as cofounder and member of the board of ReefQuest, a global organization focused on fostering marine environmental stewardship in children through citizen science. An inventor, he is
named on multiple U.S. patents and patent applications related to imaging, image processing, and nano-bio-polymer and telecommunications technologies. Mr. Vecchione studied physics at the University of California, Berkeley.
Rajeev Venkayya, M.D., is the President of Takeda’s Global Vaccine Business Unit, a vertically integrated business with a pipeline that includes vaccine candidates for norovirus and dengue. He also oversees Takeda’s contract with the U.S. Biomedical Advanced Research and Development Authority to develop a vaccine to support the Zika response in the United States and affected regions around the world. He is an independent member of the board of CEPI, the Coalition for Epidemic Preparedness Innovations, and a life member of the Council on Foreign Relations. Prior to Takeda, Dr. Venkayya served as the Director of Vaccine Delivery in the Global Health Program at the Bill & Melinda Gates Foundation, where he was responsible for the Gates Foundation’s efforts in polio eradication and new vaccine introduction, and a grant portfolio of $500 million per year. While at the Gates Foundation, he served on the Board of the Global Alliance for Vaccines and Immunization. Dr. Venkayya was previously the Special Assistant to the President for Biodefense at the White House. In this capacity, he oversaw U.S. preparedness for bioterrorism and biological threats and was responsible for the development and implementation of the National Strategy for Pandemic Influenza. He first came to Washington, DC, through the nonpartisan White House Fellowship program in 2002. Trained in pulmonary and critical care medicine, Dr. Venkayya served as an Assistant Professor of Medicine in the Division of Pulmonary and Critical Care Medicine at the University of California, San Francisco. He also served as Co-Director of the Medical Intensive Care Unit and the Director of the High-Risk Asthma Clinic at San Francisco General Hospital. Dr. Venkayya was a resident and the Chief Medical Resident in internal medicine at the University of Michigan. He completed his undergraduate and medical school education in the B.S./M.D. program at the Northeast Ohio Universities College of Medicine in the United States, where he was inducted into the Alpha Omega Alpha honorary medical society.
Sabrina Welsh, M.P.H., brings more than 10 years of international clinical trial and program management experience to her role at the Human Vaccines Project. As the Director of Programs and Operations, Ms. Welsh oversees the clinical and lab operations within the Project’s network to help the Project run efficiently to produce high-quality and impactful data. Before joining the Human Vaccines Project, Ms. Welsh worked as the Senior Clinical Program Manager for the International AIDS Vaccine Initiative (IAVI), where she led early clinical development project teams for vaccines and monoclonal antibodies for the prevention of HIV and other emerging infec-
tious diseases. She also helped develop the program for Epidemiology for Vaccine Advancement, Capacity and Science (EpiVACS) at IAVI, where her work focused on acute HIV infection and access to health care in marginalized key populations. She received an M.P.H. from the New York University College of Global Public Health and a B.S. with distinction in research from Cornell University.